Freeze-Drying Process Optimisation for a Small Molecule - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Freeze-Drying Process Optimisation for a Small Molecule


Pharmaceutical Technology Europe
Volume 24, Issue 6

Compared with biopharmaceuticals, most freeze-dried small-molecule drugs are relatively inexpensive. To make their manufacture profitable, a high throughput without compromising the final quality is indispensable. The best approach to an optimised freeze-drying cycle is the reduction of primary drying time because this phase is commonly the most time-consuming part (1, 2). To follow this approach, an accurate and representative measurement of the critical formulation temperature (CFT) is required, which poses the upper boundary for the product temperature at the sublimation interface (Tp) during primary drying (2,3). With regard to process time and product-quality attributes, such as elegantcake appearance, low residual moisture, quick and complete reconstitution and drug activity, the product temperature over time profile during primary drying should be close to but below the CFT (2–4). In some cases, however, drying in the microcollapse regime is possible without severe structural loss, as reported for protein formulations, and could also be a promising approach to further process optimisation for small molecule drugs (5–7). In this study, the thermal properties of gentamicin sulphate as a small-molecule model substance were characterised by means of freeze-dry microscopy (FDM) and differential scanning calorimetry (DSC) to determine the CFT at different concentrations and to investigate the potential for further freeze-drying cycle optimisation.

Materials and methods

The pure gentamicin sulphate drug substance used for the thermal characterisation was provided by Merck KGaA. Gentamicin sulphate solutions of 2, 5, 10, 20 and 30% (w/v) were prepared with deionised water.

DSC. The glass-transition temperature of the maximally freezeconcentrated solute (Tg') for the 5% (w/v) gentamicin sulphate solution was determined using a differential scanning calorimeter (DSC822e, Mettler Toledo). Data analysis was conducted with software (STARe Software V 9.01, Mettler Toledo) and values were provided as "onset" and "midpoint" (i.e., half height) of the transition. 30 µL of sample solution were hermetically sealed in a 40-µL aluminum pan, cooled down to -80 °C at a cooling rate of 5 °C/min, equilibrated for 10 min and reheated at 10, 3, and 1 °C/min. For one sample measured with a heating rate of 3 °C/min, an annealing step was implemented for 90 min at -20°C. Nitrogen was used to purge the measuring cell throughout the experiment.

FDM. Collapse temperatures (Tc) for the 2, 5, 10, 20 and 30% (w/v) sample solutions were investigated directly after preparation and after one week of storage at room temperature. Validation of the temperature sensor and classification of collapse behaviour were conducted according to the literature and results are reported as an average of four measurements (8). The FDM equipment consisted of a microscope (Zeiss Imager.A1 microscope, Zeiss) with a polariser, a lambda disk and a freeze-drying stage (FDCS 196, Linkam Scientific Instruments). For each measurement, a sample volume of 2 µL was pipetted onto a cover glass lying on the silver block oven of the stage. A smaller cover glass was placed on top of this drop. Constant layer thickness was assured by using custom-made metal pieces (i.e., 25 µm) as spacers. To improve thermal contact between the bottom cover glass and the oven, a droplet of silicon oil was added. The sample droplet was frozen at a rate of 1.0 °C/min and equilibrated at -45°C for 10–13 min depending on the velocity of the sublimation interface. After 8 min of equilibration, the vacuum pump was switched on and sublimation could subsequently be observed. The sample was heated at a rate of 1.0 °C/min following the equilibration step. The magnification used during the experiments was 200-fold. Pictures were captured by the software in 1-second intervals using a digital camera (Pixelink, 1.3 MP) and analysed with the LinkSys 32 software (Linkam Scientific Instruments). The stage was purged with dry nitrogen during freezing and heating. Pressure was measured using a calibrated Pirani gauge (Linkam Scientific Instruments) The maximum achievable vacuum (< 0.03 mbar) was kept constant throughout the measurement.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here